Pyridinylimidazoles as dual glycogen synthase kinase 3ß/p38[alpha] mitogen-activated protein kinase inhibitors
Self archived versionfinal draft
MetadataShow full item record
CitationHeider, Fabian. Ansideri, Francesco. Tesch, Roberta. Pantsar, Tatu. Haun, Urs. Döring, Eva. Kudolo, Mark. Poso, Antti. Albrecht, Wolfgang. Laufer, Stefan A. Koch, Pierre. (2019). Pyridinylimidazoles as dual glycogen synthase kinase 3ß/p38[alpha] mitogen-activated protein kinase inhibitors. European journal of medicinal chemistry, 175, 309-329. 10.1016/j.ejmech.2019.04.035.
Compounds simultaneously inhibiting two targets that are involved in the progression of the same complex disease may exhibit additive or even synergistic therapeutic effects. Here we unveil 2,4,5-trisubstituted imidazoles as dual inhibitors of p38α mitogen-activated protein kinase and glycogen synthase kinase 3β (GSK3β). Both enzymes are potential therapeutic targets for neurodegenerative disorders, like Alzheimer's disease. A set of 39 compounds was synthesized and evaluated in kinase activity assays for their ability to inhibit both target kinases. Among the synthesized compounds, potent dual-target-directed inhibitors showing IC50 values down to the low double-digit nanomolar range, were identified. One of the best balanced dual inhibitors presented in here is N-(4-(2-ethyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridin-2-yl)cyclopropanecarboxamide (20c) (p38α, IC50 = 16 nM; GSK3β, IC50 = 35 nM) featuring an excellent metabolic stability and an appreciable isoform selectivity over the closely related GSK3α. Our findings were rationalized by computational docking studies based on previously published X-ray structures.
Subjectskinase inhibitors pyridinylimidazoles glycogen synthase kinase 3β p38α MAP kinase dual inhibitors Alzheimer's disease
Link to the original itemhttp://dx.doi.org/10.1016/j.ejmech.2019.04.035
- Terveystieteiden tiedekunta 
Showing items related by title, author, creator and subject.
1,2,6-thiadiazinones as novel narrow spectrum calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2) Inhibitors Asquith, CRM; Godoi, PH; Counago, RM; Laitinen, T; Scott, JW; Langendorf, CG; Oakhill, JS; Drewry, DH; Zuercher, WJ; Koutentis, PA; Willson, TM; Kalogirou, AS (MDPI AG, 2018)We demonstrate for the first time that 4H-1,2,6-thiadiazin-4-one (TDZ) can function as a chemotype for the design of ATP-competitive kinase inhibitors. Using insights from a co-crystal structure of a 3,5-bis(arylamino)-4 ...Tieteelliset aikakauslehtiartikkelit
Autophagy Stimulus Promotes Early HuR Protein Activation and p62/SQSTM1 Protein Synthesis in ARPE-19 Cells by Triggering Erk1/2, p38MAPK, and JNK Kinase Pathways Marchesi, Nicoletta; Thongon, Natthakan; Pascale, Alessia; Provenzani, Alessandro; Koskela, Ali; Korhonen, Eveliina; Smedowski, Adrian; Govoni, Stefano; Kauppinen, Anu; Kaarniranta, Kai; Amadio, Marialaura (Hindawi Limited, 2018)RNA-binding protein dysregulation and altered expression of proteins involved in the autophagy/proteasome pathway play a role in many neurodegenerative disease onset/progression, including age-related macular degeneration ...Tieteelliset aikakauslehtiartikkelit
Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells Lindqvist, Julia; Imanishi, Susumu Y.; Torvaldson, Elin; Malinen, Marjo; Remes, Mika; Örn, Fanny; Palvimo, Jorma J.; Eriksson, John E. (American Society for Cell Biology (ASCB), 2015)Contrary to cell cycle–associated cyclin-dependent kinases, CDK5 is best known for its regulation of signaling processes in differentiated cells and its destructive activation in Alzheimer's disease. Recently, CDK5 has ...info:eu-repo/semantics/article